GSK Investigational Site

Voorhees Township, New Jersey 08103

0 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndrome, Crohn's Disease, HIV Infection, Heart Failure, Congestive and Microalbuminuria, Hypertension, Infection, Human Immunodeficiency Virus, Infection, Human Immunodeficiency Virus I, Neoplasms, Breast, Neoplasms, Prostate, Relapsed Breast Cancer, Systemic Lupus Erythematosus

Studies at this site

• Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry — Completed
• A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV — Completed
• COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria — Stopped early
• The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer — Completed
• Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer — Completed
• Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension — Completed
• Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults — Completed
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer — Completed
• Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer — Stopped early
• KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks — Completed